Evidence Sheet: Adobe (ADBE)
The standing BullScope yardsticks for Adobe, computed from official filings and refreshed with each new edition.
Abbott’s Split Screen: One Business Surging, One Shrinking, and a Stock Priced Somewhere in Between
Abbott spent the better part of a decade becoming something harder to categorize than a drug company. It makes the...
Netflix Is Earning More Than Ever. The Stock Is Down 37%. Both Things Are True.
The gist of it The filed numbers show a business that has nearly doubled its profit margin in four years...
Gilead’s Books Say One Thing. The Price Tag Says Another. Here’s What the Filings Actually Show.
A company reports an operating loss of more than $10 billion in a single quarter. Its stock sits within striking...
Amgen: A Bone-Drug Empire Is Shrinking While a Weight-Loss Bet Grows
Amgen built its modern commercial identity on drugs that strengthen bones and suppress immune systems. For years, Prolia and Xgeva,...
Honeywell elevates Building Automation chief to lead Process Technology as Ken West departs
Honeywell Technologies announced a leadership reshuffle on Aug. 19, 2026, promoting Billal Hammoud from President and CEO of Building Autom
Lowe’s cuts full-year profit guidance as DIY weakness persists despite Pro strength
Lowe's Companies narrowed its fiscal 2026 earnings outlook on Wednesday, reducing adjusted diluted EPS guidance to approximately $12.25 fro
Evidence Sheet: Goldman Sachs Group (GS)
The standing BullScope yardsticks for Goldman Sachs Group, computed from official filings and refreshed with each new edition.
Lowe’s Narrows the Range: What the Call Revealed That the Filing Couldn’t Hide
For most of the past decade, Lowe's has been a story of patient reinvention. The company spent years losing ground...
Goldman Sachs Is Earning Like It’s 2021. The Market Is Pricing It Like Something Better.
Goldman Sachs spent most of the last decade trading below the value of its own assets. After the 2008 crisis,...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.